Quince Therapeutics, Inc.
QNCX
$30.32
$0.822.76%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.63M | 4.27M | 3.64M | 3.28M | 3.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.09M | 11.11M | 16.24M | 11.36M | 9.90M |
| Operating Income | -22.09M | -11.11M | -16.24M | -11.36M | -9.90M |
| Income Before Tax | -75.41M | 30.57M | -36.31M | -13.49M | -15.98M |
| Income Tax Expenses | 75.00K | -5.34M | 3.15M | -46.00K | 67.00K |
| Earnings from Continuing Operations | -75.49M | 35.91M | -39.46M | -13.44M | -16.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.49M | 35.91M | -39.46M | -13.44M | -16.05M |
| EBIT | -22.09M | -11.11M | -16.24M | -11.36M | -9.90M |
| EBITDA | -22.05M | -11.08M | -16.20M | -11.33M | -9.86M |
| EPS Basic | -12.31 | 78.31 | -141.72 | -49.83 | -68.75 |
| Normalized Basic EPS | -1.81 | 29.82 | -73.28 | -25.19 | -40.03 |
| EPS Diluted | -12.31 | 78.31 | -141.72 | -49.83 | -68.75 |
| Normalized Diluted EPS | -1.81 | 29.82 | -73.28 | -25.19 | -40.03 |
| Average Basic Shares Outstanding | 6.13M | 458.60K | 278.40K | 269.80K | 233.40K |
| Average Diluted Shares Outstanding | 6.13M | 458.60K | 278.40K | 269.80K | 233.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |